PCRX

Pacira BioSciences, Inc.

Fundamental data last updated:September 26, 2026

We may earn a commission from partner links. This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate.

company profile

SECTOR

Healthcare

industry

Drug Manufacturers - Specialty & Generic

Exchange

NASDAQ

County of HQ

US

Next Earnings Date

Pending Announcement

Business Summary

Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature only to targeted nerves. It also develops proprietary multivesicular liposome, a drug delivery technology that encapsulates drugs without altering their molecular structure. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Tampa, Florida.

 


Analyze PCRX on TradingView

VALUATION

P/E

186.48

Market Cap ($M USD)

$931.45M

Forward P/E

4.51

PEG

0.00

PRICE TO SALES

1.27

PRICE TO BOOK

1.47

EV / EBITDA

10.12

5-Year Average P/E

Free Cash Flow Yield

14.25%

DCF Value

$320.12

Graham Number

$6.80

Price to FCF

7.02

EV to FCF

9.03

Earnings Yield

0.54%

FCF Yield

14.25%

DIVIDEND

Yield

0.00%

Annual Payout

$0.00

Payout Ratio

0.00%

Consecutive Years of Dividend Growth

5-Year Dividend Growth Rate

Financial Health & Profitability

Earnings Per Share

$0.13

Next Year EPS Growth Estimate

$5.25

Next Year Revenue Growth Estimate

$935.18M

Return on Equity (ROE)

0.73%

FREE CASH FLOW

Operating Margin

3.09%

Debt-to-Equity

0.66

Piotroski F-Score

8

Altman Z-Score

1.89

Return on Invested Capital (ROIC)

2.06%

Current Ratio

4.73

Quick Ratio

3.35

Net Debt to EBITDA

2.25

Interest Coverage

1.52

Gross Profit margin

79.34%

FCF PER SHARE

$3.28

REVENUE PER SHARE

$18.16

Analyze PCRX on TradingView

Gainseekers Quantitative Analysis

Summary

The market seems to be dramatically mispricing Pacira BioSciences, Inc. relative to its DCF value, which towers over the recent pricing. With a Forward P/E of 4.41, the stock appears undervalued, especially when juxtaposed with its sky-high Price/Earnings ratio of 182.30, hinting at past earnings volatility. The Altman Z-score of 1.83 raises red flags about financial distress, yet the Earnings Yield of 0.55% suggests limited immediate returns. This is a complex narrative of potential growth masked by historical challenges, demanding a discerning eye to separate the wheat from the chaff.

AI Exposure / Tech Reliance

Operating within the healthcare sector, Pacira BioSciences is poised to leverage AI advancements in drug manufacturing and specialty pharmaceuticals. The industry is ripe for tech-driven efficiencies, and companies that adapt can streamline R&D and production processes. However, the extent of their tech integration remains to be seen.

The Bull Case

For the value or GARP investor, Pacira BioSciences offers intriguing prospects. The Piotroski F-Score of 8 signals strong financial health, while a robust FCF Yield of 14.57% underscores its cash-generating prowess. Despite a modest ROIC of 1.59%, the company's operating margin of 2.38% suggests room for improvement in capital efficiency. These metrics paint a picture of a company with potential pricing power and operational resilience, making it a compelling buy for those seeking undervalued gems.

The Bear Case

However, the bear case cannot be ignored. The company's Price/Book ratio of 1.43 and Price/Sales ratio of 1.24 suggest it's not as cheap as it seems, especially when considering its low Return on Equity of 0.73%. The Altman Z-score indicates potential financial distress, and the Earnings Yield of 0.55% is underwhelming. Additionally, with the stock trading close to its 52-week high, there's a risk of technical overextension.

Market Sentiment & Smart Money

Short Interest %

Analyst Consensus

Hold

Average Analyst Price Target

$29.50

Institutional Ownership %

1-Year Beta

0.32

Insider Buying % (6 Mo)

Distance to 52-Week High

16.72%

Distance to 52-Week Low

20.61%

EARNINGS SURPRISE %

-1.64%

50-DAY SMA

$23.62

200-DAY SMA

$23.71

⚠️ Financial Disclaimer:
This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate. We may earn a commission from partner links.